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Dyrlaegevej 16, 1870 Frederiksberg C, Denmark. E-mail: mast@clin.au.dkAbstract was one dog withdrawn by the owner 7 days after crossoverObjective We aimed to assess the efficacy and benefit-
risk profile of pregabalin (PGN) to reduce the clinical
signs of central neuropathic pain (CNeP) as reflected by
scratching episodes in dogs with symptomatic syringo-
myelia (SM).
Study design Randomized, double-blind, placebo-controlled
crossover study.
Animals A total of 12 client-owned Cavalier King Charles
Spaniels (age, 1.1e7.4 years, bodyweight, 8.2e10.8 kg)
with magnetic resonance imaging-confirmed SM and clin-
ical signs of CNeP.
Methods Dogs were randomized to either PGN 150 mg or
placebo for 25 days, followed by 48 hour washout period
before crossover to the alternate phase of 25 days. The
primary outcome was defined as number of scratching
events during 10 minutes of video-recorded physical ac-
tivity. Treatment effect was estimated using a generalized
estimation equation model. Benefit-risk and quality of life
assessments were obtained through owner interviews
focusing on potential adverse events.
Results The treatment effect estimate was an 84% (95%
confidence interval ¼ 75e89%) reduction in mean number
of scratching events relative to baseline compared with
placebo (p < 0.0001). Owner-assessed satisfactory quality of
life was status quo and rated as ‘good’ or ‘could not be
better’ in six/11 dogs and improved in four/11 dogs. The
most prevalent adverse events were increased appetite in
nine/12 dogs and transient ataxia in nine/12 dogs. There238to PGN owing to persistent ataxia. No dogs needed rescue
analgesia during the trial.
Conclusions and clinical relevance PGN is superior to
placebo in the reduction of clinical signs of SM-related CNeP
in dogs. At a dose range of 13e19 mg kge1 orally twice
daily, the encountered adverse events were acceptable to all
but one owner.
Keywords analgesia, canine chronic pain, Chiari-like
malformation, clinical pharmacology, neuralgia, spinal cord
disorder.Introduction
Symptomatic syringomyelia (SM) and concomitant Chiari-like
malformation (CM) is a neurological syndrome that occurs in
up to 15% of Cavalier King Charles Spaniels (CKCS) (Thøfner
et al. 2015). The clinical phenotype is diverse and includes
both physical and behavioural indicators of hypersensitivity,
discomfort and pain (Rusbridge et al. 2007; Rutherford et al.
2012; Hechler & Moore 2018). Common clinical signs are
spontaneous and evoked scratching, phantom scratching and
paroxysmal pain manifestations with vocalization (Rusbridge
& Jeffery 2008; Cerda-Gonzalez et al. 2009). Furthermore,
aberrant behaviours including nightwandering, hiding,
avoidance of touch and grooming and reluctance to wear a
collar or harness are reported by the owners (Rusbridge et al.
2000; Sanchis-Mora et al. 2016; Sparks et al. 2018).
There are no prescription drugs labelled for use in animals
with chronic or neuropathic pain. Non-steroidal anti-inflam-
matory drugs, corticosteroids, opioids, gabapentinoids, the N-
Pregabalin in canine central neuropathic pain MS Thoefner et al.methyl-D-aspartate antagonist amantadine, serotonin-
norepinephrine reuptake inhibitors and tricyclic antidepres-
sants have been suggested for the management of chronic and
neuropathic pain in general and symptomatic SM in CKCS
(Rusbridge 2005; Mathews 2008; Rusbridge & Jeffery 2008;
Grubb 2010; Plessas et al. 2012; KuKanich 2013; Epstein
et al. 2015; Plessas et al. 2015; Moore 2016; Hechler &
Moore 2018).
The antiepileptic compound pregabalin (PGN) is a first-line
analgesic in the evidence-based guidelines on pharmaco-
therapy for neuropathic pain in humans (Finnerup et al.
2015). The primary target is the a2-d-subunit of the voltage-
gated calcium channels in the central nervous system (Gong
et al. 2001; Marais et al. 2001). PGN inhibits the calcium-
mediated release of excitatory neurotransmitters resulting in
analgesic and anticonvulsant effects (Li et al. 2004; Taylor
et al. 2007; Bauer et al. 2009).
The pharmacokinetics of 4 mg kge1 PGN administered orally
has been investigated in six adult Labrador/Greyhound dogs
(Salazar et al. 2009). The maximal plasma concentration was
7.15 (4.6e7.9) mg mLe1, which occurred after 1.5 (1.0e4.0)
hours. The elimination half-life was 6.9 (6.21e7.4) hours, and
no adverse effects were seen. The extra-label PGN dosage for
dogs with neuropathic pain is 2e4 mg kge1 twice to thrice
daily at 8 or 12 hour intervals (Plumb 2015; Hechler &Moore
2018). The clinical use of PGN as an add-on anticonvulsant
and analgesic has been sparsely reported (Dewey et al. 2009;
Plessas et al. 2012; Bhatti et al. 2015).
Up to 25% of symptomatic CKCS with SM are euthanized
due to inadequate treatment (Plessas et al. 2012; Thofner
et al. 2015). Acknowledging the unmet need of evidence-
based treatment recommendations, the primary aim of the
study was to assess the efficacy and benefit-risk profile of
PGN in CKCS with SM-related central neuropathic pain
(CNeP). We hypothesize that the analgesic efficacy of PGN is
superior to placebo in reducing the clinical signs of SM-
related CNeP.
Materials and methods
The study protocol was approved by the Danish Medicines
Agency (11 April 2017, file number 2017020400) and the
local Ethics and Administration Committee (20 February
2017, file number 2017-4). Informed consent was obtained
from all owners.
Study population
Eligible dogs were client-owned, purebred CKCS, older than 1
year and weighing 8e12 kg, with clinical signs of SM-related
CNeP. They were defined as uni- or bilateral spontaneous
scratching directed at the cervical or shoulder area. SM was
defined as a fluid-filled cavity in the spinal cord parenchyma© 2019 Association of Veterinary Anaesthetists and American College of Veterina
open access article under the CC BY-NC-ND license (http://creativecommons.orgwith a diameter  2 mm confirmed on T1-weighted magnetic
resonance imaging (MRI). Owners had to be willing to
administer an ectoparasite prophylaxis (e.g. fipronil, imida-
cloprid/permethrin or fluralaner) before inclusion. Exclusion
criteria were pregnant or lactating bitches, dogs treated with
analgesics 48 hours prior to inclusion, dogs with clinical signs
of other neurological disorders than SM, dogs that scratched
solely at the ears or face, dogs scratching due to other causes
than SM and dogs with clinical findings contraindicating
anaesthesia.
Pre-inclusion assessment
Pre-inclusion assessments were undertaken by the principal
investigator (PI; MST) and a dedicated research veterinary
technician. A questionnaire (Rutherford et al. 2012) was
used to assess the dog’s general health status, medical his-
tory, clinical signs and behaviour to confirm eligibility. In
addition, the owners were asked to rate their dog’s quality of
life (QOL) as ‘could not be better’, ‘good’, ‘fairly good’,
‘neither good nor bad’, ‘fairly poor’, ‘poor’, ‘could not be
worse’ or ‘do not know’. The dogs were video-documented
walking on a predefined route for 10 minutes to confirm
the expression of quantifiable spontaneous scratching and to
enable retrospective reassessment of the dogs’ scratching
profiles and quantification of scratching events. All dogs
underwent a clinical and neurological examination including
otoscopy and ear swab cytology. Urine analysis, haemogram,
biochemical and thyroid profile were undertaken before MRI
of the neurocranium and cervical spinal cord parenchyma
(Thoefner et al. 2019).
Study design
This superiority trial was designed as a two-treatment two-
period crossover trial. Dogs were randomly assigned to treat-
ment arm A with sequence ‘PGN➝ placebo’ or treatment arm
B with sequence ‘placebo ➝ PGN’ (Fig. 1). The intended allo-
cation ratio was 1:1. The owner was asked to withdraw a
random number from a nontransparent envelope. The random
number corresponded to a unique trial code on a randomiza-
tion list previously generated (www.randomization.com). The
list was provided in a sealed envelope by the pharmacist who
manufactured, packed and labelled the containers with the
unique trial code and ‘treatment period one’ or ‘treatment
period two’. They contained identical gelatine capsules of
either 150 mg of PGN (Lyrica; Pfizer, NY, USA) or placebo.
Thus, randomization to treatment arm A or B was blinded to
the PI and the owner. The owners were blinded to treatment to
eliminate any biased expectation of effect. The trial was
continuously followed by an external monitor. The PI, owners,
monitor and statistician were blinded to the treatment
sequence allocation.ry Anesthesia and Analgesia. Published by Elsevier Ltd. This is an
/licenses/by-nc-nd/4.0/)., 47, 238e248
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All dogs were administered PGN orally. In treatment arm A,
150 mg of PGN was administered once daily for 2 days
increasing to a targeted maintenance dose of 150 mg twice
daily for 21 days. This was followed by a tapering phase of 150
mg once a day for 2 days. A 48 hour washout period was
followed by crossover to the placebo-treatment period: one
capsule once daily for 2 days, one capsule twice daily for 21
days, followed by one capsule once a day for 2 days. In treat-
ment arm B, dogs were administered placebo treatment firstly,
followed by PGN using the same dosage protocol as described
for treatment arm A. The 150 mg dose twice daily was based
on a pilot study and pharmacological data (Salazar et al.
2009).
Discontinuation and rescue analgesia
The owners and PI could withdraw the dogs from the study at
any time. Discontinuation was indicated in case of noncom-
pliance to the protocol, failure to respond or deterioration of the
dog’s QOL. In case of failure to respond or clinical deterioration,
rescue analgesia with firocoxib 5 mg kge1 once daily for 48
hours would be provided by the PI. In case of insufficient
analgesia, add-on treatment with PGN 75 mg kge1 once daily
for 48 hours followed by 75 mg kge1 twice daily for 7 days
would be prescribed. A weekly assessment and up-titration
with additionally 25 mg kge1 twice daily should proceed.
This was continued until a clinically overt reduction in
scratching events and other indicators of discomfort and pain
were obtained without side effects. Adverse events that indi-
cated discontinuation were anorexia, vomitus or repeated ep-
isodes of prolonged deep sedation.
Outcome measures
The outcomes were assessed on five occasions: during the pre-
inclusion assessment, when baseline data were collected, and
at four follow-up visits (two in each treatment period) on days
7, 21, 34 and 48 ± 2.
The primary outcome ‘number of scratching events during
10 minutes of continuous physical activity’ was chosen based
on previous reports on the most prevalent clinical signs in
symptomatic CKCS with SM (Rusbridge et al. 2000, 2007;
Sanchis-Mora et al. 2016; Sparks et al. 2018). The dogs’
scratching profiles were documented in standardized video-
series of 10 minute duration and quantified by counting
scratching episodes.
Secondary outcome measures for intensity of scratching and
pain or discomfort during the preceding 24 hours were
assessed by the owner using two separate scales. They con-
sisted of an 11 point numerical rating scale (NRS; 0 ¼ no
scratching/no pain or discomfort, 10 ¼ worst scratching/pain© 2019 Association of Veterinary Anaesthetists and American College
open access article under the CC BY-NC-ND
240or discomfort imaginable) and a modified children’s Faces Pain
Scale (FPS-M; Fig. 2a) combined with a visual analogue scale
(VAS). It consisted of five faces, a colour-intensity scale
beneath the faces and a horizontal sliding indicator on the front
of the FPS-M (Hicks et al. 2001). On the reverse side was a pre-
printed 0e100 mm VAS scale (Fig. 2b). The owners were
asked to place the sliding indicator on the colour or face that
corresponded to their assessment. The PI subsequently read
the corresponding VAS score on the reverse side. Finally, the
owner was asked to rate the dog’s QOL by the same descriptors
as listed under the pre-inclusion visit.
The PI rated the dog’s scratching intensity and pain/
discomfort, respectively, by means of the same NRS and FPS-M
as the owner after each visit. In addition, the PI assessed the
dog’s QOL by the same descriptors as the owner based on the
history, clinical findings and overall subjective impression of
clinical efficacy of the treatment on number of scratching
events and stress level.
The owners were given a diary at enrolment to log de-
viations of medicine administration from the predefined time,
the daily scratching intensity, SCRATCH/NRS and to docu-
ment any adverse events and other observations during the
trial period. At each follow-up visit, the dogs’ body weight was
recorded and the owners were asked a series of questions to
monitor adverse events. The questions addressed activity level
(normal/reduced/hyperactive), aggression (towards other
people/animals, yes/no), appetite (normal/increased/
decreased), ataxia (yes/no), behavioural changes (yes/no: if
yes, please describe), faecal score (normal/hard/moist/watery),
food intake (normal/increased/decreased), sleeping pattern
(normal/reduced sleeping activity/somnolence), vomiting (yes/
no), water intake (normal/increased/decreased) and details on
their dog’s scratching phenotype (intensity compared with
baseline, anatomical localization, phantom scratching yes/no)
and if the dog was chewing paws (yes/no).
The remaining capsules were counted at each follow-up visit
to account for end-of-trial owner compliance. The proportion
of capsules given relative to the expected number of capsules
given at each follow-up visit was used to categorize owners as
‘satisfactory adherent’ (90% capsules administered correctly)
or ‘suboptimal administrator’ (80% and 90% capsules
administered correctly) (Pullar et al. 1989; Dodd et al. 2012).
The owners were asked for a final preference statement
(treatment period one or two) at the end-of-trial visit to assess
the efficacy of blinding.
Dimensioning of the study
A minimum sample size of 13 was calculated based on a
normal distribution approximation using a ¼ 0.05 and b ¼
0.8. It was assumed that the mean number of scratching epi-
sodes during 10 minutes of exercise would be reduced by 20%of Veterinary Anesthesia and Analgesia. Published by Elsevier Ltd. This is an
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., 47, 238e248
RANDOMIZATION OF 
ELIGIBLE, SYMPTOMATIC 
CM-SM-POSITIVE CKCS
TREATMENT 
ARM A
DAY 0
BASELINE DATA COLLECTED
TREATMENT 
ARM B
DOSE ESCALATION PHASE 
Pregabalin 150 mg once daily DAY 1–2
DOSE ESCALATION PHASE 
Placebo 1 capsule once daily
FIXED DOSE TREATMENT PHASE
Pregabalin 150 mg twice daily DAY 3–23
FIXED DOSE PLACEBO PHASE
Placebo 1 capsule twice daily
FOLLOW-UP VISIT I DAY 7 (+/–2)
FOLLOW-UP VISIT II DAY 21 (+/–2)
TAPER PHASE
Pregabalin 150 mg once daily DAY 24–25
TAPER PHASE
Placebo 1 capsule once daily
WASHOUT PERIOD
48 HOURS DAY 26–27
WASHOUT PERIOD
48 HOURS
DOSE ESCALATION PHASE 
Placebo 1 capsule once daily DAY 28–29
DOSE ESCALATION PHASE 
Pregabalin 150 mg once daily
FIXED DOSE PLACEBO PHASE
Placebo 1 capsule twice daily DAY 30–50
FIXED DOSE TREATMENT PHASE
Pregabalin 150 mg twice daily
FOLLOW-UP VISIT III DAY 34 (+/–2)
FOLLOW-UP VISIT IV DAY 48 (+/–2)
TAPER PHASE
Placebo 1 capsule once daily DAY 51–52
TAPER PHASE
Pregabalin 150 mg once daily
END OF TRIAL
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Pregabalin in canine central neuropathic pain MS Thoefner et al.using the placebo (Vasseur et al. 1995; McMillan 1999) and by
75% using PGN (pilot data). To account for drop-outs, capsules
with PGN and placebo were prepared for a total of 20 dogs. The
calculated sample size was used as a guideline since the applied
assumptions were only applicable for a simple t test study
design. A blinded interim analysis was planned when 13 dogs
had completed the trial. The decision was made acknowledging
the lack of appropriate sample size calculation tools for the
applied repeated measurements design’s complex data struc-
ture and correlation analysis (Guo et al. 2013). The dataset
was completed and locked, and the code was not broken until
data analyses were finalized. Accordingly, the last-patient-last-
visit defined the end of trial.
Statistical analysis
Datawere analysedwith SAS Studio version 3.71 (SAS Institute
Inc., NC, USA), and p < 0.05 was considered significant. Cate-
gorical variables are reported as frequencies and proportions
and continuous data as medians and ranges. The primary
outcome ‘number of scratching events’ is, however, reported as
mean and range. Since ‘number of scratching events’ is a
countable variable, a negative binomial distributionwas used to
model it, allowing for overdispersion (compared with a Poisson
distribution). The effect of treatment of PGN and placebo,
period, follow-up visit number and potential carryover was
modelled using a log-link (i.e. multiplicative effects), and a
generalized estimating equation was applied to account for the
correlation of scratching events over time for the same dog
(Zeger & Liang 1986). The effect estimates are given as ratios,
such as of PGN versus placebo. Treatment effect on owner- and
PI-assessed SCRATCH/NRS, SCRATCH/VAS, PAIN/NRS and
PAIN/VAS was modelled by means of a general linear mixed
model as was the effect on bodyweight after log-transformation
(Liang & Zeger 1986). Cross-tabulations were made to assess
the agreement between the owners and PI with regards to their
assessment of SCRATCH/NRS, SCRATCH/VAS, PAIN/NRS,
PAIN/VAS and the dogs’ QOL. Data were included in the
analysis when dogs had participated in at least three of four
consecutive follow-up visits. If owners answered a question
with ‘do not know’, data were excluded from analysis.
Results
A total of 81 potential cases were consecutively assessed for
eligibility betweenMarch 2017 and June 2018 (Fig. 3). Of these,Figure 1 Trial design. The trial was designed as a two-treatment two-p
expressing clinical signs consistent with Chiari-like malformation (CM) and
to treatment arm A [treatment sequence pregabalin (PGN) ➝ placebo] or
treatment period was of 25 days duration separated by a 48 hour washout p
administered once daily. In the fixed dose treatment phase, 150 mg PGN
assessed at baseline and at follow-up visits IeIV (two visits in each treatm
© 2019 Association of Veterinary Anaesthetists and American College
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24212 dogs were included in the analysis (n ¼ 4 in treatment arm
A; n¼ 8 in treatment arm B). The last follow-up visit was in July
2018. No dogs needed rescue analgesia during the trial.
The 12 participants (six females, one ovariohysterectomized
female, four males and one castrated male) were 3.6 (1.1e7.4)
years old and weighed 8.7 (8.2e10.8) kg at baseline. The
overall mean number of scratching events during 10 minutes
of continuous physical activity was 9.1 (2e27). Additional
MRI findings were CM in 12/12 dogs, unilateral otitis media
with effusion in two/12 dogs and bilateral otitis media with
effusion in four/12 dogs.
Treatment effect
The treatment effect of PGN on the mean number of scratching
events was estimated to be a factor 0.16 [95% confidence in-
terval (CI)¼ 0.11e0.25]. It corresponded to an 84% reduction
from baseline in the mean number of scratching events during
10 minutes of continuous physical activity compared with
placebo (p < 0.0001). No significant effect was found of pla-
cebo, period, follow-up visit number or carryover on the pri-
mary outcome. In addition, the scratching profile changed
during treatment with PGN. The phantom scratch stopped in
seven/eight dogs (88%) and vocalization when scratching
ceased in five/five dogs (100%) compared with baseline.
Efficacy estimates of PGN revealed a significant reduction in
owner- and PI-reported scratching and pain intensity
(Table 1). Only the effect of PGN on owner-assessed mean
PAIN/NRS was not significantly different from the effect of
placebo compared with baseline (p ¼ 0.056).
Quality of life
The dogs' QOL data are shown in Table 2. There was one
owner who was unable to assess the dog’s QOL at baseline.
Compared with baseline, treatment with PGN resulted in
improved QOL in two/four dogs (50%) allocated to arm A (PGN
➝ placebo) and in two/seven (29%) dogs allocated to arm B
(placebo ➝ PGN). The status of one dog allocated to arm B
changed from ‘good’ in the first follow-up visit after crossover
to PGN to ‘fairly good’ at the end of trial owing to an owner-
assessed increased appetite. After crossover from PGN to pla-
cebo, the owner-assessed QOL deteriorated in three/four dogs
(75%) compared with baseline in arm A, and remained status
quo in four/seven dogs (57%) in arm B from baseline to the end
of the placebo period. In the remaining three/seven dogs (43%)eriod crossover study. Eligible Cavalier King Charles Spaniels (CKCS)
syringomyelia-related (SM) central neuropathic pain were randomized
treatment arm B (placebo ➝ PGN) after baseline data collection. Each
eriod. During the dose escalation and taper phase, 150 mg of PGN was
was administered twice daily. Primary and secondary outcomes were
ent period).
of Veterinary Anesthesia and Analgesia. Published by Elsevier Ltd. This is an
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., 47, 238e248
Figure 2 The modified Faces Pain Scale. The scale was used to assess each dog’s scratching and pain intensities at baseline and four follow-up
visits. The sliding indicator was placed on a face or colour corresponding to the dog’s scratching intensity during the last 24 hours by the owner as
shown in (a). The SCRATCH/VAS and PAIN/VAS scores were subsequently read from the back side by the principal investigator (b). Translation of
the Danish wording: ‘Ingen smerte’, no pain. ‘Værst tænkelig smerte’, worst imaginable pain. Depicted and reproduced with permission from
MEDshop.dk (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article).
Pregabalin in canine central neuropathic pain MS Thoefner et al.of arm B, the changes were a result of a change in weather.
The owners reported a decrease in their dogs’ activity level
owing to extreme summer heat (the summer of 2018 was the
warmest summer for 140 years in Denmark). A cross-
tabulated comparison in QOL revealed agreement between
the owner and PI in 30/58 assessments (52%). In 21 of the
remaining 28 assessments, the owner evaluated a better QOL,
which was significantly more often than the PI (p ¼ 0.016).
Additional information reported by the owners
According to the owners’ diary records, the clinical effect of
PGN was observable 48e72 hours after administration.
External factors that affected the owners’ daily SCRATCH/NRS
ratings were wearing a harness or a collar (six dogs) and flea
infestation (two dogs), which was promptly treated, in arm B
during treatment period two. Increased scratching intensities
during oestrus were reported in two females during the trial.
Reluctance to take medication was reported in three dogs, and
four owners found it difficult to fit the 12 hour dosing interval
into their daily routines.
Dose range and adverse events
The administered dose was 13e19 mg kge1 twice daily. The
body weight of included dogs ranged from 8.0 to 11.4 kg.
Despite the reported increase in appetite and a clinically overt© 2019 Association of Veterinary Anaesthetists and American College of Veterina
open access article under the CC BY-NC-ND license (http://creativecommons.orgweight gain in four dogs, the 2.1% increase (95% CI ¼ 0.4%e
4.6%) in mean body weight during PGN treatment was
nonsignificant (p < 0.099). The weight gain was more evident
in four dogs fed ad libitum compared with the other seven dogs
whose owners were more attentive to restricted feeding.
The incidences of owner-reported adverse events are pre-
sented in Table 3. The most prevalent adverse events following
PGN administration were increased appetite and transient
ataxia, which resolved between days 1 to 10. A reduced activity
level was reported in four/12 dogs (33%), and two/12 dogs
(17%) were assessed to be hyperactive. An increased water
intake was reported by four/12 owners (33%) at the first follow-
up visit after PGN administration was initiated. The water intake
was normalized in all dogs at the second follow-up in the PGN
treatment period. The reported adverse events were acceptable
for all but one owner. This owner withdrew his dog as a result of
ataxia and somnolence. No serious adverse events, such as
death or hospitalization occurred during the trial.
Compliance
The overall owner compliance was 98% (range 93%e105%).
An “over-compliance” of 105% (46 capsules administered in
44 days) resulted from one owner administering the capsules
every 12 hours from day 1 (instead of day 3) in period two. All
owners in treatment arm B and two owners in treatment arm
A (50%) were categorized as ‘satisfactory adherent’ at all fourry Anesthesia and Analgesia. Published by Elsevier Ltd. This is an
/licenses/by-nc-nd/4.0/)., 47, 238e248
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Figure 3 Trial profile. Recruitment was initiated in January 2017. A total of 81 owners and veterinarians responded to the recruitment notices.
Of the 81 enquiries, 17 potential cases (21%) were continuously assessed and 13 dogs were included in the study between March 2017 and June
2018. MMVD, myxomatous mitral valve disease; SM, syringomyelia.
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Table 1 The effect of pregabalin 150 mg twice daily on scratching and pain intensity in 12 dogs
Owner-assessed p PI-assessed p
Baseline mean Treatment effect (95% CI) Baseline mean Treatment effect (95% CI)
Scratching intensity
NRS, 0e10 4.0 e2.7 (e4.4, e1.0) 0.003 5.2 e2.7 (e4.2, e1.1) 0.002
VAS, 0e100 mm 43 e33 (e46, e19) <0.0001 53 e29 (e46, e12) 0.001
Pain intensity
NRS, 0e10 2.6 e2.1 (e4.3, 0.05) 0.06 4.2 e4.1 (e5.6, e2.6) <0.0001
VAS, 0e100 mm 34 e24 (e42, e6) 0.01 44 e44 (e59, e29) <0.0001
CI, confidence interval; NRS, numeric rating scale; PI, principal investigator; VAS, visual analogue scale.
Table 2 Incidence of quality of life (QOL) descriptors at baseline and during the trial. Data are shown as % and (the number of dogs given the
specific QOL descriptor/the total number of dogs allocated to the specific treatment arm in that phase of the study)
Treatment arm A Baseline Pregabalin Placebo
Follow-up I Follow-up II Follow-up III Follow-up IV
Owner PI Owner PI Owner PI Owner PI Owner PI
QOL descriptor
Could not be better 25 (1/4) 0 25 (1/4) 25 (1/4) 50 (2/4) 25 (1/4) 25 (1/4) 0 0 0
Good 50 (2/4) 75 (3/4) 50 (2/4) 75 (3/4) 50 (2/4) 75 (3/4) 50 (2/4) 50 (2/4) 25% (1/4) 25% (1/4)
Fairly good 25 (1/4) 0 25 (1/4) 0 0 0 0 25 (1/4) 75% (3/4) 50% (2/4)
Neither good nor bad 0 25 (1/4) 0 0 0 0 25 (1/4) 0 0 0
Bad 0 0 0 0 0 0 0 25 (1/4) 0 25% (1/4)
Treatment arm B Baseline Placebo Pregabalin
Follow-up I Follow-up III Follow-up IVy
Owner * PI Owner PI Owner PI Owner PI Owner PI
QOL descriptor
Could not be better 28.5 (2/7) 0 0 0 12.5 (1/8) 0 50 (4/8) 50 (4/8) 28.5 (2/7) 57 (4/7)
Good 28.5 (2/7) 12.5 (1/8) 37.5 (3/8) 37.5 (3/8) 37.5 (3/8) 37.5 (3/8) 37.5 (3/8) 37.5 (3/8) 57 (4/7) 28.5 (2/7)
Fairly good 43 (3/7) * 62.5 (5/8) 62.5 (5/8) 37.5 (3/8) 37.5 (3/8) 50 (4/8) 12.5 (1/8) 12.5 (1/8) 14 (1/7) 14 (1/7)
Neither good nor bad 0 12.5 (1/8) 0 12.5 (1/8) 12.5 (1/8) 12.5 (1/8) 0 0 0 0
Bad 0 12.5 (1/8) 0 12.5 (1/8) 0 0 0 0 0 0
*The owner of one dog was unable to assess the animal’s QOL.
yAfter follow-up III, one animal was withdrawn from the trial.
Pregabalin in canine central neuropathic pain MS Thoefner et al.follow-up visits. During the placebo period, two treatment arm
A owners (50%) were categorized as ‘suboptimal
administrators’.
Final preference statement
All 12 owners preferred the period in which their dog had
received PGN over the placebo period despite blinding to
treatment allocation and the reported adverse events.
Discussion
This study demonstrates that PGN significantly alleviated the
clinical signs of SM-related CNeP in CKCS. The treatment ef-
fect’s relatively wide confidence interval of 75e89% reflects© 2019 Association of Veterinary Anaesthetists and American College of Veterina
open access article under the CC BY-NC-ND license (http://creativecommons.orgthe small sample size and the clinical variation between dogs.
This variation may be caused by several factors. According to
the owners, scratching was more evident on the day of a
follow-up visit. Transportation, often by car, entering the
hospital facility and wearing a collar or harness during video
recordings are external stressors that may have intensified
scratching (Rusbridge et al. 2000; Rutherford et al. 2012). The
flea infestation in two dogs probably increased scratching ac-
tivity as well. Oestrus was reported to increase the scratching
intensity and duration in two intact bitches. Aggravation of
scratching as a consequence of cycle-dependent intensification
of pain and reduced sensory threshold was described in rodent
pain models and humans (Iacovides et al. 2015). Whether it
was the cause of increased scratching in the entire bitchesry Anesthesia and Analgesia. Published by Elsevier Ltd. This is an
/licenses/by-nc-nd/4.0/)., 47, 238e248
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Table 3 Incidence of adverse events recorded during the study. Data
are derived from the 12 dogs included in the study
Adverse events Treatment
Pregabalin Placebo
Incidence (%)
Activity level
Reduced 33 (4/12) 8 (1/12)
Hyperactive 17 (2/12) 8 (1/12)
Aggression 0 0
Ataxia 75 (9/12) 8 (1/12)
Fecal texture: moist 8 (1/12) 8 (1/12)
Food intake
Hypophagia 8 (1/12) 33 (4/12)
Polyphagia 75 (9/12) 17 (2/12)
Paw chewing 0 0
Sleeping pattern: somnolence 8 (1/12) 0
Vomiting 0 0
Water intake
Reduced 0 8 (1/12)
Increased 33 (4/12) 8 (1/12)
Pregabalin in canine central neuropathic pain MS Thoefner et al.remains unknown. An initial reluctance among some dogs to
accept oral administration of PGN potentially resulted in
plasma concentrations below the therapeutic level at the first
follow-up visit. This clinical variation may have been reduced
by stratification of bitches by neuter status and by avoiding
collars and harnesses. By incorporating repeated ectoparasite
prophylaxis and a run-in period in the protocol, flea in-
festations could have been avoided and dogs could have been
accustomed to oral administration of capsules.
A clinical challenge is the lack of quantifiable biomarkers of
pain and a gold standard of pain assessment in veterinary
patients (Mathews 2008). VAS and NRS are accepted in the
human pain research community as valid for self-reporting of
pain severity (Attal et al. 2010, 2018). Facial coding systems
are used for carers to rate pain in babies who are unable to self-
report pain (Hicks et al. 2001). Owing to the inherent lack of
verbal communication with animals, the FPS-M was used in
the present study. No canine facial coding systems or grimace
scales are available. This was a limitation of the study since the
FPS-M has not been validated for assessment of scratching and
pain/discomfort intensities in dogs. Opposed to the PI, owners
did not understand their dog’s scratching intensity as an
indication of pain or discomfort. This could explain the
nonsignificant effect of PGN on the owner-assessedPAIN/NRS.
The screening questionnaire published by Rutherford et al.
(2012) was used in the present study to assess the eligibility
of potential cases before inclusion in the trial. It consists of a 5-
point neuropathic pain score (NPS) based on owner ratings in
seven clinical manifestations of symptomatic SM: persistent
compulsive scratching, facial rubbing, hypersensitivity to© 2019 Association of Veterinary Anaesthetists and American College
open access article under the CC BY-NC-ND
246touch, unexplained yelping, reluctance to lift the head, reluc-
tance to bend the neck to eat and reluctance or pain when
defaecating. The NPS was not developed for and has not been
validated to assess treatment effect. The authors of the present
study argue that facial rubbing and reluctance or pain when
defaecating are not inevitably synonymous with symptomatic
SM. The NPS was accordingly deselected as an outcome
measure in the present trial.
The ChiMPS-T questionnaire was published after the initi-
ation of the present study (Sparks et al. 2018). This clinical
screening and assessment tool addresses the medical history,
frequency and severity of symptoms and includes a pain and
scratch map to outline the dog’s affected body areas. The
ChiMPS-T questionnaire was unable to establish an association
between the presence of pain or scratching and SM in 30 SM-
affected dogs. There was a lack of correlation between the
presence of pain determined after neurological examination
and the owner-reported presence of pain, pain score and
affected body area as indicated on the pain and scratch map.
These findings emphasize the need for objective, quantifiable
biomarkers of pain in veterinary clinical research.
The use of QOL assessment introduced another limitation to
the present study. The dog’s physical and mental status, social
behaviour and function are among the factors that are entailed
in the concept of a good QOL from the owner’s perspective.
Factors that define a good QOL for some owners are less or not
important to others. In the present study, a majority of the
owners did not juxtapose their dogs’ physical and behavioural
indicators of discomfort and pain with a suboptimal QOL.
Accordingly, it was only possible to achieve an actual
improvement in owner-assessed QOL in one-third of the
included dogs.
The dose rationale of the present study was founded on a
very careful benefit-risk assessment based on our pilot study
and a previous pharmacological study (Salazar et al. 2009).
Here, we aimed to identify the dose that resulted in a beneficial
clinical effect and at the same time to avoid unwanted adverse
events and risks to the dogs. The most frequently occurring side
effect in the present study was transient ataxia. The ataxia was
subjectively described by all but one owner as acceptable and
resolved between days 1 to 10 in 8/12 dogs (66%). By contrast,
ataxia was not seen in the dogs included in the pilot study. One
possible explanation is the difference in PGN administration
dose regimens. Dogs included in the pilot study were initially
given the extra-label PGN dosage of 2e4 mg kge1 twice daily
(Plumb 2015; Hechler & Moore 2018). Subsequently, PGN
was titrated to effect. Hence the concentration was slowly
increased over several weeks. Conversely, the PGN dose was
up-titrated from 13e19 mg kge1 once daily to twice daily
during 48 hours. The plasma concentration increased more
rapidly in the present study, which probably explains the
initial, transient ataxia. The other frequently occurring adverseof Veterinary Anesthesia and Analgesia. Published by Elsevier Ltd. This is an
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., 47, 238e248
Pregabalin in canine central neuropathic pain MS Thoefner et al.event was an increased appetite and resultant increase in body
weight in dogs fed ad libitum. When owners became aware of
the weight gain, restricted feeding was initiated and no further
weight gain was seen.
This is the first double-blind, placebo-controlled crossover
study to report that PGN results in a highly significant
reduction in clinical signs of SM-related CNeP in CKCS.
Treatment with PGN maintained or improved a satisfactory
owner-assessed QOL in 10/11 dogs. Transient ataxia and
increased appetite were acceptable adverse events to all but
one owner. The present study found that the number of
scratching events, phantom scratching and vocalization when
scratching can be used as pharmacological responsive, quan-
tifiable indirect biomarkers of pain. The results of this short-
term study support a positive treatment effect. To assess if
long-term administration of PGN is safe in dogs, a longitudinal
cohort study with continuous monitoring of effective plasma
PGN concentration and potential adverse effects on organ
systems is needed.
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